We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Destiny Pharma Plc | DEST | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.00 | 3.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 28/8/2024 11:41 by timbo003 Still activity and interest despite the company now being delisted and in administration, although I'm not sure that shareholders will end up with much (or anything) even if the administrators achieve an optimal outcome:It is good to see that there is renewed interest in inhaled XF drugs for Cystic Fibrosis, I have always thought that CF might be the best way in for first approval and the news today concerning QIDP status for XF-73 Dermal to treat burn wound infections will help attract interest from potential investors or acquirers |
Posted at 09/8/2024 10:31 by zen12 Personally I think they already have a pre-agreement in place with an investor(s), otherwise why would one go through all the pain and cost of delisting on a suggestion. After delisting I suspect magically funding to arrive. |
Posted at 15/7/2024 06:04 by bones698 Ouch there it is. A complete mess so delistimg. What a didaster for investors. |
Posted at 10/5/2024 08:16 by briankrakow So they've announced their AGM:The statement says: "Shareholders are invited to submit any questions for the Board to consider." In other words, they want to avoid any difficult questions just like they do on the Investor meet company presentations. I'm not impressed at all. Bad sign. |
Posted at 26/4/2024 11:23 by sev22 A link to yesterday's Investor Meet Company Presentation - Final Results. |
Posted at 25/4/2024 07:39 by idomeneo No licensing deal for XF-73 nasal: Despite engaging with potential partners and receiving positive feedback, Destiny Pharma has not been able to secure a licensing deal for XF-73 nasal that they believe provides fair value to the company and its shareholders. This lack of a deal could be seen as a setback by investors.Uncertainty about the future of XF-73 nasal: The company is now undertaking a review of strategic options to determine how best to advance XF-73 nasal through Phase 3 clinical trials. This review introduces uncertainty about the future development path of the product, which could make investors nervous. Potential need for additional financing: As part of the strategic review, Destiny Pharma is considering the possibility of securing finance to enable it to conduct the Phase 3 clinical studies itself. This suggests that the company may need to raise additional funds, which could dilute existing shareholders or be seen as a risk if the financing is not secured. Perception of the commercial potential of antibiotics: The announcement mentions that potential partners have expressed concerns about the prevailing perceptions of the commercial potential of antibiotics. This could indicate a broader market sentiment that may be affecting the valuation of companies working in this space. While the announcement also highlights some positive developments, such as the partnership with Sebela Pharmaceuticals and the potential cost savings from a new clinical trial design for XF-73 nasal, the overall tone of the update seems to have introduced more uncertainty and potential challenges, which could explain the negative market reaction. |
Posted at 28/3/2024 11:42 by john henry TBH i can see many young Biotech stocks going private,Unfortunately UK investors will not see the growth. |
Posted at 07/3/2024 11:05 by cyberbub Just filter them, some people never left primary school in their minds. Not worthy of any decent investors' time to get involved in their playground name-calling. Certainly don't respond - it only gives them the attention they crave. |
Posted at 02/2/2024 19:38 by ttlance Amazing how sentiment has changed here. Only 2 weeks ago there was massive optimism, lording TC and highlighting how XF-73 was going to change the infection market. Investors have been truly suckered into this stock. Investors enjoying the share price rise in the last 9 months have put their own narrative to this, thinking it was a one way bet. |
Posted at 22/1/2024 17:57 by 2cmb Investors Arab3. I would call them investors with patience. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
